Valuation : Paradigm Biopharmaceuticals Limited

Market Cap 119M 85.45M 73.35M 68.67M 62.88M 118M 8.16B 813M 318M 4.11B 321M 314M 13.61B P/E 2026
-0.92x
P/E 2027 * -2.41x
Enterprise Value 84.8M 61M 52.36M 49.02M 44.89M 84.56M 5.83B 580M 227M 2.94B 229M 224M 9.72B EV / Sales 2026
-
EV / Sales 2027 * -
Free-Float
91.43%
Yield 2026 *
-
Yield 2027 * -
1 day+5.00%
1 week+20.00%
Current month+27.27%
1 month+23.53%
3 months+20.00%
6 months-19.23%
Current year-38.24%
1 week 0.18
Extreme 0.175
0.24
1 month 0.16
Extreme 0.157
0.24
Current year 0.14
Extreme 0.135
0.37
1 year 0.14
Extreme 0.135
0.47
3 years 0.14
Extreme 0.135
0.78
5 years 0.14
Extreme 0.135
2.69
10 years 0.14
Extreme 0.135
4.5
Manager TitleAgeSince
Chief Executive Officer - 2022-11-21
Director of Finance/CFO - 2023-03-02
Chief Operating Officer - -
Director TitleAgeSince
Chairman - -
Director/Board Member 60 2020-12-08
Director/Board Member - 2024-03-03
Date Insider Type Main position Quantity % Market Cap.
6/2/26 Buy

Chief Executive Officer

176,470 0.0336%
6/2/26 Buy

Chief Executive Officer

176,470 0.0336%
6/2/26 Buy

Chief Executive Officer

176,470 0.0336%
Change 5-day change 1-year change 3-year change Capi.($)
+5.00%+20.00%-27.59%-70.42% 85.45M
-0.78%-1.42%+2.49%+22.78% 51.14B
-6.60%-0.65%+443.00%+545.09% 47.4B
-0.05%+0.87%+38.87%+18.17% 43.19B
-2.01%-2.16%+22.96%+81.30% 42.35B
-0.31%-1.75%+17.23%+52.37% 33.23B
-0.85%-2.20%+28.37%+132.04% 17.07B
-0.83%-2.06% - - 16.38B
-0.88%-0.66%+11.60%+27.75% 14.76B
-1.05%-0.56%+79.85%+47.69% 14.15B
Average -0.80%+2.06%+68.53%+95.20% 27.98B
Weighted average by Cap. -1.75%+1.12%+99.22%+137.83%

Financials

2026 2027 *
Net sales - -
Net income -36.3M -26.11M -22.41M -20.98M -19.22M -36.2M -2.49B -248M -97.14M -1.26B -98.04M -95.92M -4.16B -44.8M -32.23M -27.66M -25.9M -23.71M -44.67M -3.08B -307M -120M -1.55B -121M -118M -5.13B
Net Debt -34M -24.46M -20.99M -19.65M -18M -33.9M -2.34B -233M -90.98M -1.18B -91.82M -89.84M -3.9B -12M -8.63M -7.41M -6.94M -6.35M -11.97M -824M -82.14M -32.11M -415M -32.41M -31.71M -1.38B
Logo Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited is a late-stage drug development company engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). PPS is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans. It develops PPS under the brand name Zilosul. Other indications under investigation for PPS include the treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses; treating alphavirus-induced arthralgia; chronic heart failure; acute respiratory distress syndrome; and allergic respiratory conditions. It is also advancing early formulation development for Pentacoxib, an oral combination of PPS and a COX-2 inhibitor targeting patients with earlier-stage OA.
Employees
-
Date Price Change Volume
26-08-28 A$0.2100 +5.00% 1,508,003
26-08-27 A$0.2000 -11.11% 3,084,022
26-08-26 A$0.2250 0.00% 2,951,035
26-08-25 A$0.2250 +12.50% 6,916,909
26-08-24 A$0.2000 +14.29% 8,241,711
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.2000AUD
Average target price
1.080AUD
Spread / Average Target
+440.00%

Annual profits - Rate of surprise